Brief: Transgene/BioInvent: positive data regarding their BT-001 product

Transgene SA

09/11/2021 13:08

Nov 9 (Reuters) - Transgene Sa  TRNG.PA /BioInvent: 
    * TRANSGENE AND BIOINVENT PRESENT PRECLINICAL DATA
HIGHLIGHTING
THE ROBUST ANTI-TUMORAL ACTIVITY OF BT-001 ONCOLYTIC VIRUS AT
SITC 2021
    * THIS LATEST DATA SUPPORT BT-001'S UNIQUE DUAL MODE OF
ACTION
    * THIS DATA DEMONSTRATE HIGH INTRATUMORAL EXPRESSION OF AN
IMMUNE
CHECKPOINT-INHIBITING ANTIBODY AND ROBUST ANTI-TUMORAL ACTIVITY
IN SEVERAL TUMOR MODELS.

Source text for Eikon:  ID:nBw5TlBq9a 
Further company coverage:  TRNG.PA 

 (Reporting by Sudip Kar-Gupta)
 ((sudip.kargupta@thomsonreuters.com;))